References
- 1. Barakat MT, Meeran L, Bloom SR. Neuroendocrine tumors. Endocr Relat Cancer. 2004 Mar;11(1):1-18. DOI: 10.1677/erc.0.0110001
- 2. Oberndorfer S. Karzinoide tumoren des dunndarms. Frank Z Pathol. 1907;1:426-432.
- 3. Salazar R, Wiedenmann B, Rindi G, Ruszniewski P. ENETS 2011 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update. Neuroendocrinology. 2012;95(2):71-3. DOI: 10.1159/000335600
- 4. Pinchot S, Holen K, Sippel R, Chen H. Carcinoid Tumors. Oncologist. 2008;13(12):1255-1269. DOI: 10.1634/theoncologist.2008-0207
- 5. Bellizzi AM. Assigning site of origin in metastatic neuroendocrine neoplasms: a clinically significant application of diagnosis immunohistochemistry. Adv Anat Pathol. 2013 Sep;20(5):285-314. DOI: 10.1097/ PAP.0b013e3182a2dc67
- 6. Fisher-Colbrie R, Hagn C, Schober M. Chromogranins A, B, C: widespread consitituents of secretory vesicles. Ann N Y Acad Sci. 1987;493:120-34. DOI: 10.1111/ j.1749-6632.1987.tb27189.x
- 7. Bajetta E, Ferrari L, Martinetti A, Celio L, Procopio G, Artale S, et al. Chromogranin A, neuron specific enolase, carcinoembryonic antigen, and hydroxyindole acetic acid evaluation in patients with neuroendocrine tumors. Cancer. 1999;86(5):858-865. DOI: 10.1002/ (SICI)1097-0142(19990901)86:5<858::AID-CNCR23> 3.0.CO;2-8
- 8. Iacangelo AL, Eiden LE. Chromogranin A: current status as a precursor for bioactive peptide and a granulogenic/sorting factor in the regulated secretory pathway. Regul Pept. 1995 Aug 22;58(3):65-88. DOI: 10.1016/0167-0115(95)00069-N
- 9. Poiană C, Neamţu MC, Avramescu ET, Carşote M, Trifănescu R, Terzea D, et al. The poor prognosis factors in G2 neuroendocrine tumor. Rom J Morphol Embryol. 2013;54(3 Suppl):717-20.
- 10. Poiană C, Neamţu MC, Avramescu ET, Carşote M, Trifănescu R, Terzea D, et al. The dedifferentiation of neuroendocrine tumor metastases: myth or reality? Rom J Morphol Embryol. 2013;54(1):201-3.
- 11. Groth CM, Banzon ER. Octreotide for the treatment of hypoglycemia after insulin glargine overdose. J Emerg Med. 2013 Aug;45(2):194-8. DOI: 10.1016/j. jemermed.2012.11.099
- 12. Vinik Al, Silva MP, Woltering EA, Go VL, Warner R, Caplin M. Biochemical testing for neuroendocrine tumors. Pancreas. 2009;38(8):876-89. DOI: 10.1097/ MPA.0b013e3181bc0e77
- 13. Lawrence B, Gustafsson Bl, Kidd M, Pavel M, Svejda B, Modlin M. The clinical relevance of chromogranin A as a biomarker for gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40(1):111-34. DOI: 10.1016/j.ecl.2010.12.001
- 14. Poiană C, Carşote M, Neamtu MC, Avramescu ET, Vasilescu F, Terzea D, et al. Well-differentiated neuroendocrine tumor and osteoporosis: incidental finding? Rom J Morphol Embryol. 2013;54(4):1169-71.
- 15. Oberg K, Norheim I, Theodorsson E. Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol. 1991;30(4):503-7. DOI: 10.3109/02841869109092409
- 16. Panzuto F, Di Fonzo M, Iannicelli E, Sciuto R, Maini CL, Capurso G, et al. Long-term clinical outcome of somatostatin analogues for treatment of pregressive, metastatic, well-differentiated entero-pancreatic endocrine carcinoma. Ann Oncol. 2006;17(3):461-6. DOI: 10.1093/annonc/mdj113
- 17. Butturini G, Bettini R, Missiaglia E, Mantovani W, Dalai I, Capelli P, et al. Predictive factors of efficacy of the somatostatin analogue octreotide as first line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer. 2006;13(4):1213-21. DOI: 10.1677/ erc.1.01200